Increasing chronic kidney disease cases are driving growth in complicated UTI treatment market
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Forecasted Market Size Trajectory Of The Complicated Urinary Tract Infection Treatment Market From 2026 To 2030?
The complicated urinary tract infection treatment market size has seen robust growth in recent years. This market is expected to increase from $9.44 billion in 2025 to $10.04 billion in 2026, registering a compound annual growth rate (CAGR) of 6.4%. Historically, this expansion can be linked to the rising incidence of catheter-associated infections, increasing antibiotic resistance, an expanding aging population, developing hospital infrastructure, and improved diagnosis of chronic urinary disorders.
The complicated urinary tract infection treatment market size is anticipated to demonstrate substantial growth in the upcoming years. It is projected to expand to $12.74 billion in 2030, achieving a compound annual growth rate (CAGR) of 6.1%. This expansion during the forecast period is driven by factors such as the development of innovative antibiotics, an increase in the immunocompromised patient population, wider adoption of outpatient infusion therapies, rising healthcare expenditures, and enhanced pathogen identification technologies. Prominent trends throughout this period include the optimization of empiric therapy, an increase in the use of broad-spectrum antibiotics, a rise in hospitalizations for complicated UTIs, a growing preference for combination drug therapies, and the expansion of hospital pharmacy-based dispensing.
Access Your Free Sample Report For In-Depth Market Analysis:
Which Drivers Are Supporting The Complicated Urinary Tract Infection Treatment Market Growth?
The increasing occurrence of chronic kidney diseases is anticipated to boost the expansion of the complicated urinary tract infection treatment market in the future. Chronic kidney disease (CKD) represents a progressive, enduring ailment marked by a slow decline in kidney function across a period. This growing prevalence of Chronic kidney disease (CKD) primarily stems from rising rates of diabetes and hypertension, coupled with an aging demographic and lifestyle elements like obesity and smoking. Treatment for complicated urinary tract infections aids chronic kidney disease (CKD) patients by averting serious infections, including pyelonephritis, which could intensify kidney harm, deteriorate renal capabilities, and hasten the advancement of chronic kidney disease, thereby lowering the likelihood of subsequent complications and hospital admissions. As an illustration, figures from June 2024, provided by the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that in 2023, chronic kidney disease accounted for 1.1% of the total disease burden in Australia. Consequently, the growing frequency of chronic kidney diseases acts as a primary driver for the complicated urinary tract infection treatment market.
Which Segment Classifications Are Used In The Complicated Urinary Tract Infection Treatment Market Segment Analysis?
The complicated urinary tract infection treatment market covered in this report is segmented –
1) By Drug Class: Penicillin And Combinations, Quinolones, Cephalosporin, Azoles And Amphotericin B, Nitro Furans
2) By Distribution Channel: Hospital Pharmacies, Gynecology And Urology Clinics, Drug Stores
3) By Application: Urethritis, Cystitis, Pyelonephritis
Subsegments:
1) By Penicillin And Combinations: Aminopenicillins, Beta-Lactamase Inhibitor Combinations
2) By Quinolones: Fluoroquinolones, Non-Fluoroquinolones
3) By Cephalosporin: First-Generation Cephalosporins, Second-Generation Cephalosporins, Third-Generation Cephalosporins, Fourth-Generation Cephalosporins, Fifth-Generation Cephalosporins
4) By Azoles And Amphotericin B: Triazoles, Imidazoles, Polyene Antifungals
5) By Nitrofurans: Nitrofurantoin, Furazolidone
Which Trends Are Expected To Impact The Complicated Urinary Tract Infection Treatment Market?
Companies within the complicated urinary tract infection treatment market are concentrating on developing novel antibiotics to combat antibiotic resistance, aiming to enhance treatment efficacy and address emerging multidrug-resistant pathogens. Anti-infective therapies for complicated urinary tract infection treatment involve employing targeted antibiotics or antimicrobial agents to eliminate or control infections, particularly in severe cases where kidney involvement is present. For example, in February 2024, Allecra Therapeutics, a Germany-based biopharmaceutical company, announced the U.S. Food and Drug Administration (FDA) approval of EXBLIFEP (cefepime/enmetazobactam) for treating complicated urinary tract infections (cUTIs) in adults. The company also secured a five-year marketing exclusivity extension under the GAIN Act, which incentivizes the development of new anti-infective therapies. A study demonstrated that 79.1% of patients treated with cefepime/enmetazobactam achieved a composite response (clinical cure and microbiological eradication) compared to 58.9% of those treated with piperacillin/tazobactam.
Which Firms Are Contributing To The Complicated Urinary Tract Infection Treatment Market Ecosystem?
Major companies operating in the complicated urinary tract infection treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., AstraZeneca PLC, Fresenius Kabi AG, GlaxoSmithKline plc, bioMérieux SA, Shionogi & Co. Ltd., Cipla Limited, Santen Pharmaceutical Co. Ltd., Orchid Pharma Limited, Melinta Therapeutics Inc., Spero Therapeutics Inc., Nabriva Therapeutics AG, Venatorx Pharmaceuticals Inc., Recce Pharmaceuticals Ltd, MerLion Pharmaceuticals Pte. Ltd., Entasis Therapeutics Holdings Inc., Allecra Therapeutics GmbH, Allergan Inc.
Get The Full Complicated Urinary Tract Infection Treatment Market Report:
Which Region Leads The Complicated Urinary Tract Infection Treatment Market In Terms Of Market Share?
North America was the largest region in the complicated urinary tract infection treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the complicated urinary tract infection treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Complicated Urinary Tract Infection Treatment Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Complicated Urinary Tract Infection Treatment Market 2026, By The Business Research Company
Chlamydia Infection Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/chlamydia-infection-treatment-global-market-report
Uncomplicated Urinary Tract Infection Treatment Market Report 2026
Pediatric Bladder Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/pediatric-bladder-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
